Renee D. Gala's most recent trade in Dexcom Inc was a trade of 5,074 Common Stock done . Disclosure was reported to the exchange on May 8, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Dexcom Inc | Renee D. Gala | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 May 2025 | 5,074 | 10,794 (0%) | 0% | 0 | Common Stock | |
| Dexcom Inc | Renee D. Gala | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Mar 2025 | 5,720 | 5,720 (0%) | 0% | 0 | Common Stock | |
| Jazz Pharmaceuticals plc | Renee D. Gala | President & COO | Sale or transfer of securities back to the company at price $ 138.95 per share. | 05 Mar 2025 | 5,704 | 88,895 (0%) | 0% | 139.0 | 792,571 | Ordinary Shares |
| Jazz Pharmaceuticals plc | Renee D. Gala | President & COO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Feb 2025 | 23,111 | 83,044 (0%) | 0% | 0 | Ordinary Shares | |
| Jazz Pharmaceuticals plc | Renee D. Gala | President & COO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Feb 2025 | 11,555 | 94,599 (0%) | 0% | 0 | Ordinary Shares | |
| Jazz Pharmaceuticals plc | Renee D. Gala | President & COO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jan 2025 | 7,741 | 63,233 (0%) | 0% | 0 | Ordinary Shares | |
| Jazz Pharmaceuticals plc | Renee D. Gala | President & COO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 122.62 per share. | 17 Jan 2025 | 3,300 | 59,933 (0%) | 0% | 122.6 | 404,646 | Ordinary Shares |
| Jazz Pharmaceuticals plc | Renee D. Gala | President & COO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 123.45 per share. | 05 Dec 2024 | 80 | 55,492 (0%) | 0% | 123.5 | 9,876 | Ordinary Shares |
| Jazz Pharmaceuticals plc | Renee D. Gala | President & COO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 115.21 per share. | 05 Apr 2024 | 1,736 | 55,357 (0%) | 0% | 115.2 | 200,005 | Ordinary Shares |
| Jazz Pharmaceuticals plc | Renee D. Gala | President & COO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 117.53 per share. | 05 Mar 2024 | 3,622 | 57,093 (0%) | 0% | 117.5 | 425,694 | Ordinary Shares |
| Jazz Pharmaceuticals plc | Renee D. Gala | President & COO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2024 | 19,916 | 60,715 (0%) | 0% | 0 | Ordinary Shares | |
| Jazz Pharmaceuticals plc | Renee Gala D. | President & COO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jan 2024 | 7,079 | 44,003 (0%) | 0% | 0 | Ordinary Shares | |
| Jazz Pharmaceuticals plc | Gala Renee D. | President & COO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 119.13 per share. | 17 Jan 2024 | 3,204 | 40,799 (0%) | 0% | 119.1 | 381,693 | Ordinary Shares |
| Gossamer Bio Inc | Renee D. Gala | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2023 | 35,000 | 35,000 | - | - | Stock Option (Right to Buy) | |
| Jazz Pharmaceuticals plc | Renee D. Gala | EVP & Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 131.75 per share. | 18 May 2023 | 6,000 | 35,978 (0%) | 0% | 131.7 | 790,474 | Ordinary Shares |
| Jazz Pharmaceuticals plc | Renee D. Gala | EVP & Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 145.78 per share. | 05 Apr 2023 | 1,807 | 41,978 (0%) | 0% | 145.8 | 263,424 | Ordinary Shares |
| Jazz Pharmaceuticals plc | Renee D. Gala | EVP & Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Mar 2023 | 12,784 | 45,342 (0%) | 0% | 0 | Ordinary Shares | |
| Jazz Pharmaceuticals plc | Renee D. Gala | EVP & Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 142.78 per share. | 03 Mar 2023 | 1,557 | 43,785 (0%) | 0% | 142.8 | 222,308 | Ordinary Shares |
| Jazz Pharmaceuticals plc | Renee D. Gala | EVP & Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 160.00 per share. | 21 Dec 2022 | 2,635 | 32,558 (0%) | 0% | 160 | 421,600 | Ordinary Shares |
| Gossamer Bio Inc | Renee D. Gala | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2022 | 30,000 | 30,000 | - | - | Stock Option (Right to Buy) | |
| Jazz Pharmaceuticals plc | Renee D. Gala | EVP & CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 162.88 per share. | 05 Apr 2022 | 1,633 | 34,995 (0%) | 0% | 162.9 | 265,983 | Ordinary Shares |
| Jazz Pharmaceuticals plc | Renee D. Gala | EVP & CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Mar 2022 | 11,730 | 37,348 (0%) | 0% | 0 | Ordinary Shares | |
| Jazz Pharmaceuticals plc | Renee D. Gala | EVP & CFO | Sale or transfer of securities back to the company at price $ 153.96 per share. | 03 Mar 2022 | 720 | 36,628 (0%) | 0% | 154.0 | 110,851 | Ordinary Shares |
| Gossamer Bio Inc | Renee D. Gala | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2021 | 23,500 | 23,500 | - | - | Stock Option (Right to Buy) | |
| Jazz Pharmaceuticals plc | Renee D. Gala | EVP & CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 164.71 per share. | 05 Apr 2021 | 1,515 | 25,347 (0%) | 0% | 164.7 | 249,536 | Ordinary Shares |
| Jazz Pharmaceuticals plc | Renee D. Gala | EVP & CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Feb 2021 | 10,115 | 26,862 (0%) | 0% | 0 | Ordinary Shares |